AzurRx (AZRX) Corporate Media Kit

30 Open-Label, Multicenter, 2x2 Crossover Trial to assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis DSMB Review 30 patients across 15 sites in the U.S. and Poland anticipated Phase 2b CF OPTION 2 Enteric Dose-Escalation Trial (Initiated Q3 2020)